In the Zzz zone: the effects of Z-drugs on human performance and driving.
Level 5 - mechanism / opinion, no new human data
Narrative review without reported systematic search or meta-analytic pooling
PubMed 23456542 · doi:10.1007/s13181-013-0294-y
What was done
This narrative review synthesized literature on the adverse effects of non-benzodiazepine hypnotics (zolpidem, zopiclone, and zaleplon) on human cognition, behavior, psychomotor performance, and driving ability. The abstract does not report specific literature search methods, databases, or inclusion numbers.
What was found
Patients taking zopiclone and zolpidem have an increased risk of motor vehicle collisions that is over double that of unexposed drivers. Driving impairment is present with zopiclone and higher doses of zolpidem, but is reported to be unlikely after 4 hours following zaleplon administration. Z-drugs (especially longer half-life agents, higher doses, or combinations with alcohol/psychoactive substances) are also associated with complex behaviors (sleepwalking, sleep-driving, hallucinations), anterograde amnesia, psychomotor deficits, falls, and hip fractures.
Why it matters
Despite their pharmacokinetic profile, Z-drugs carry serious residual safety risks including a doubled crash risk. Prescribers must counsel patients on dose-dependent residual effects and enforce minimum time intervals before driving or operating machinery.
Limits
The abstract describes a narrative review rather than a systematic review with meta-analytic pooling. No primary sample sizes, exact statistical estimates (beyond the doubled collision risk estimate), or confidence intervals are provided. Confounding by underlying insomnia or concurrent medications cannot be evaluated from the abstract alone.
Cited by
- supports Zolpidem (Ambien) can induce amnesia.